combination in this year acquires entire 3-month turnovers in the collective financial statement including the high increase of sales volume of cleanser and medical supplies due to the Company becomes greatly
last year, while gross profit margin was slightly strengthened from 6.83% in 1H/2016 to 7.89% in 1H/2017. Other income in 1H/2017 amounted to Baht 741.35 million, a surge by Baht 375.49 million or 102.63
combined with the quarterly financial statement ended on 31 December 2018, but the combination in this year acquires entire 12-month turnovers in the collective financial statement including the high
, Thailand. Tel. 02-634-0225 Fax 02-634-0135 www.interpharma.co.th 2. Costs of sales and gross profit Costs of sales were Baht 117 .60 million in the first nine months of 2019, a surge of Baht 32 .42 million
2023 Agenda 2 • Motivation & Research Questions • Data • Methodology & Result • Key Takeaways The surge in sustainable investing and the dematerialized world trends has strengthened, drawing increased
related corporate tax transaction, the normalized net profit would be approximately THB 97.42 million or a surge of 48% yoy. Page 3 of 4 Statement of Financial Position as of March 31, 2019 The consolidated
March 2018 increased by 19% yoy mainly from the surge of provisions for employee benefit and other liabilities. Most of the increase of other liabilities was income tax payable on 2017 profit because
% 51.41 63.64% 4. Livestock 11.47 3.62% 9.27 2.50% (2.20) (19.18%) Total Sales revenues 316.83 100.00% 371.33 100.00% 54.50 17.20% Such growth was driven by a surge in revenues from sales of companion
www.interpharma.co.th Inter Pharma Co. Ltd. 140/9 ITF Tower, 9th Floor, Silom Road, Suriyawong, Bangrak, Bangkok 10500, Thailand. Tel. 02-634-0225 Fax 02-634-0135 www.interpharma.co.th a surge in revenues from sales of